Outcomes and risk factors of COVID-19 in patients with bullous pemphigoid: a cross-sectional study
The COVID-19 pandemic posed significant challenges for BP patients. Our study found that the use of prednisone at a dose >10 mg/day in the last three months was associated with an increased risk of SARS-CoV-2 infection. Vaccination provided protection against SARS-CoV-2 infection and severe COVID-19 in BP patients.
Authors
- Yuling Shi (ORCID: https://orcid.org/0000-0002-1273-7881)
- Yuexin Zhang (ORCID: https://orcid.org/0000-0001-7972-413X)
- Dawei Huang (ORCID: https://orcid.org/0000-0003-0732-1467)
- Yangfeng Ding (ORCID: https://orcid.org/0000-0002-0287-2190)
- Yunlu Gao (ORCID: https://orcid.org/0009-0006-2357-7912)
Institutions
- Tongji University (CN)
- Shanghai Skin Disease Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-25
- DOI
- https://doi.org/10.3389/fimmu.2025.1568801
- Citations
- 1
- Primary Topic
- Autoimmune Bullous Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- National Natural Science Foundation of China
- Tongji University